Navigation Links
YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
Date:6/23/2009

ival (p = 0.0018) favoring nimotuzumab. The addition of nimotuzumab did not add to the toxicities of either regimen, with no Grade III/IV skin toxicities observed. The trial demonstrates that the efficacy of nimotuzumab compares favorably to results reported for cetuximab, an EGFR-targeting antibody marketed as Erbitux(R), but that this efficacy was not accompanied by the severe toxicities reported in patients treated with cetuximab.

YM BioSciences today posted a series of documents on its website, www.ymbiosciences.com that address frequently asked questions made by the investment community and pharmaceutical industry relating to YM's products and business strategy. A comprehensive description of the completed and ongoing trials being conducted by YM and the other licensees of nimotuzumab is also available at YM's website.

About YM BioSciences

YM BioSciences Inc. is a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development. The Company is currently developing two late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM), and AeroLEF(R), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation. It is significantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its approval for marketing in more than 12 countries. In more
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013  Yongye International, Inc. (NASDAQ: YONG ... and distributor of crop nutrient products in ... that, on May 16, 2013, the special committee (the ... of Directors") was provided a letter (the "Letter") issued ... ) Limited ("Abax") to Full Alliance International Limited ("Full ...
(Date:5/17/2013)... 2013  Insero Health, Inc., a company developing natural ... related neurological disorders, is today reporting top-line results from ... in patients with drug-resistant epilepsy.  The data are being ... Xll meeting by Dr. Steven Schachter ... Scientific Advisory Board.  In this study, INS001 appeared safe ...
(Date:5/17/2013)... 17, 2013 The paradigm of ‘one ... systems that can help predict the adverse and therapeutic ... Stepaniants, Head of Computational Biology at the Genomics Laboratory, ... to ensure high-quality genomics when used as part of ... to complex data sets to identify key clinical targets ...
(Date:5/17/2013)... Seattle, WA (PRWEB) May 17, 2013 Rust ... several metals and non-metal home items could be damaged. To ... advised the use of its no-scrubbing rust remover ... would be able available with 10% discount. , My Cleaning ... – by corroding them or by staining them. The ...
Breaking Biology Technology:Yongye International Provides Update on Status of Proposed Go Private Offer 2Yongye International Provides Update on Status of Proposed Go Private Offer 3Yongye International Provides Update on Status of Proposed Go Private Offer 4Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2Organic-Based Rust Remover Cuts Down Price by 10%, My Cleaning Products Details Mechanics How to Get the Discount 2
... 8, 2011 Bellicum Pharmaceuticals, Inc. today announced ... cells (DCs) to conventionally matured DCs, in the ... Clinical Investigation (JCI).  The studies, conducted by ... feasibility of a second generation DeCIDe™ vector that ...
... The National Foundation for Cancer Research (NFCR) announced today that ... Szent-G y o rgyi Prize ... Jack Schultz Chair in Basic Science at the Fox Chase ... discoveries of the relationship between development and cancer, based on ...
... Management teams specializing in facilities, systems, and ... (biopharmaceuticals, vaccines, biotherapeutics and biodiagnostics) will meet at ... Aug. 8-9 at the Hilton San Diego ... The conference will detail management experience, lessons ...
Cached Biology Technology:Journal of Clinical Investigation Publishes Data Demonstrating Enhanced Antitumor Efficacy of Second Generation DeCIDe™ Technology 26th Annual Szent-Gyorgyi Prize for Progress in Cancer Research Awarded to Beatrice Mintz, Ph.D. 26th Annual Szent-Gyorgyi Prize for Progress in Cancer Research Awarded to Beatrice Mintz, Ph.D. 36th Annual Szent-Gyorgyi Prize for Progress in Cancer Research Awarded to Beatrice Mintz, Ph.D. 4Bioprocessing Facilities 2011 Conference to be held Aug. 8-9 in San Diego 2
(Date:5/18/2013)... An increasing number of U.S. children are ... according to research presented at Digestive Disease Week ... researchers at the Cleveland Clinic Children,s Hospital found ... exhaled breath compared to their lean counterparts. The ... that can be correlated to potential complications associated ...
(Date:5/17/2013)... ages will celebrate the science and technology of ... lives during the inaugural Atlanta Science Festival, March ... local museums, corporations, K-12 schools and universities, the ... for children and adults at venues across the ... , The annual Atlanta Science Festival is a ...
(Date:5/17/2013)... human-caused climate change may have little impact on ... of recent studies that predict their widespread extinction ... which appear in the journal Global Change ... a creature thought to be doomed: http://onlinelibrary.wiley.com/doi/10.1111/gcb.12253/abstract ... especially forest lizards, will be hard hit by ...
Breaking Biology News(10 mins):New research identifies risks, interventions for children's GI health 2New research identifies risks, interventions for children's GI health 3First Atlanta Science Festival set for 2014 2Climate change may have little impact on tropical lizards 2
... - Ben Major, PhD, assistant professor of cell and ... Institutes of Health Director,s New Innovator Awards, one of ... grant will fund his work to address a significant ... that functionally contribute to specific cellular and disease processes ...
... COPD and is difficult to treat. In a recent study ... a new equation to calculate the energy requirement for underweight ... to better treatment results and, ultimately, better quality of life ... Journal of Chronic Obstructive Pulmonary Disease , the study involved ...
... Biodiversity decreases towards the poles almost everywhere in ... Investigating fossil clams and snails Steffen Kiel and Sven ... that this unusual pattern originated at the end of ... The retreating glaciers created a mosaic landscape of countless ...
Cached Biology News:UNC scientist receives NIH director's New Innovator Award 2Disappearing glaciers enhanced biodiversity 2
...
Performance, mycoplasma, virus, and endotoxin tested. Collected from calves 14 days old or less...
...
Mus musculus junctophilin 2 (Jph2) Antigen: Recombinant Protein...
Biology Products: